Role of 5α-reductase inhibitors in benign prostatic diseases

  title={Role of 5$\alpha$-reductase inhibitors in benign prostatic diseases},
  author={Faris Azzouni and James L. Mohler},
  journal={Prostate Cancer and Prostatic Diseases},
  • F. AzzouniJ. Mohler
  • Published 1 September 2012
  • Biology, Medicine
  • Prostate Cancer and Prostatic Diseases
Testosterone is the most abundant androgen in serum. Intracellularly, testosterone is converted to dihydrotestosterone, the preferred ligand for androgen receptor transactivation, by the enzyme 5α-reductase. Three 5α-reductase isozymes have been discovered and they are expressed ubiquitously in human tissues. Testosterone and dihydrotestosterone have different but complimentary functions. Dihydrotestosterone has 2–5 times higher binding affinity for the androgen receptor than testosterone, and… 

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats

It is suggested that Corni Fructus water extract may weaken the BPH status through the inactivation of at least 5α-reductase and AR activity and may be useful for the clinical treatment of BPH.

Endocrine control of benign prostatic hyperplasia

It is clear that the BPH pathogenesis and the subsequent onset of the lower urinary tract symptoms (LUTS) depends from different etio‐pathogenetic factors whose mechanism of action remains to be evaluated.

Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia

Current pharmacotherapy targets either the static part of BPH, including finasteride and dutasteride, or the dynamic component of B PH, including α-adrenoceptor antagonists such as tamsulosin and alfuzosin, which significantly interfere with the apoptosis machinery.

Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5‐alpha reductase inhibitor treated human benign prostate hyperplasia patients

The pathways associated with failure of medical therapy for benign prostatic hyperplasia and medication‐refractory lower urinary tract symptoms were characterized.

Impact of pharmacologic therapy for benign prostatic hyperplasia on prostate volume and free testosterone and consequently on urinary parameters and sexual desire in men

Hormonal component of pharmacologic therapy for BPH most effectively reduces PV and freeT levels, improves urinary symptoms with a slight decline of sexual desire in men on finasteride monotherapy.

A review of the effects and molecular mechanisms of dimethylcurcumin (ASC‐J9) on androgen receptor‐related diseases

The effects and molecular mechanisms of ASC‐J9 on various AR‐associated diseases are summarized and the future applications of ASC-J9 in AR‐ associated disease control are discussed.

Steroidogenesis Mechanism, Disruption Factor, Gene Function, and Role in Male Fertility : A Mini Review

This study shows that several factors influence the course of steroidogenesis such as Leydigcells, steroidogenesis proteins, related genes to the influence of free radicals, and these factors are closely related to diet and lifestyle.

Effects of Roystonea Regia (D-004) and Saw Palmetto Lipid Extracts in Men with Symptomatic benign Prostatic Hyperplasia

D-004 (320 mg/day), a lipid extract of Roystonea regia fruits, reduced experimental prostate hyperplasia in rodents and the International Prostate Symptoms Score (IPSS) as effectively as SP in a pilot trial in men with BPH.



5α-Reductase Isozymes in the Prostate.

The analyses of 5α-reductases in humans and animals highlight the differences between testosterone and DHT, and the significance of DHT in male sexual differentiation and prostate physiology and pathophysiology.

Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency.

The clinical, biochemical and molecular genetic analyses of 5alpha-reductase-2 deficiency highlight the significance of DHT in male sexual differentiation and male pathophysiology.

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

Dutasteride appeared to be well tolerated with an adverse event profile similar to placebo and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk of acute urinary retention and prostate surgery.

Clinical application of 5α-reductase inhibitors

Finasteride appears be useful for BPH, baldness and hirsutism treatment, and the dual inhibitors should be more indicated for treatment of BPH and baldness, and in attempting to prevent prostatic cancer.

The influence of finasteride on the development of prostate cancer.

Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

In men with benign prostatic hyperplasia, terazosin was effective therapy, whereas finasteride was not, and the combination of terazOSin and finasterside was no more effective than terazoshin alone.